JX10 / Biogen, TMS Co, Ji Xing Pharma - LARVOL DELTA

Anti-Inflammatory Thrombolytic JX10 (TMS-007) in Late Presentation of Acute Ischemic Stroke. (PubMed, Stroke) - "JX10 was well tolerated and may expand the acute ischemic stroke therapeutic window as a novel thrombolytic agent. URL: https://rctportal.niph.go.jp/en; Unique identifier: jRCT2080223786."

Clinical • Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

DESIGN OF DAISY, A TWO-PART, PHASE 2B, PLACEBO-CONTROLLED RANDOMISED TRIAL OF THE EFFICACY AND SAFETY OF BIIB131 ADMINISTERED 4.5–24 HOURS AFTER ISCHAEMIC STROKE (ESOC 2023) - "BIIB131 (TMS-007) uniquely induces thrombolysis by promoting plasminogen-fibrin binding with potential anti-inflammatory properties... Data from DAISY will determine the optimal dose, efficacy and safety of BIIB131 4.5– 24 hours after LKW in patients with AIS."

Clinical • P2b data • Cardiovascular • Ischemic stroke

A first-in-human study of the anti-inflammatory profibrinolytic TMS-007, an SMTP family triprenyl phenol. (PubMed, Br J Clin Pharmacol) - "TMS-007 is generally well tolerated and exhibits favorable pharmacokinetic profiles that warrant further clinical development."

Journal • P1 data • Cardiovascular • Hematological Disorders • Ischemic stroke

Results From A Phase 2a Study Of TMS-007, An SMTP Family Anti-inflammatory Prothrombolytic, On Patients With Acute Ischemic Stroke Up To 12 Hours After Onset (ISC 2022) - "TMS-007 may expand the treatment time window for the treatment of AIS. Due to the small study size, more data on efficacy is warranted in patients with visible occlusion."

Clinical • P2a data • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammation • Ischemic stroke • Thrombosis

"$BIIB pretty much keeps on pushing their readouts Jan 2020 July 2020 BIIB111 end 2020 H1 2021 BIIB054 H2 2020 H1 2021 TMS 007 end 2020 H1 2021" (@BursatilBiotech)